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A plasmid pAc373GMCSF was constructed and co-transfected into Spodoptera frugiperda (Sf9) cells with wild-type Autographa californica nuclear 
polyhedrosis virus (AcNPV) DNA. The recombinant virus vAc373GM-CSF was identified and purified by several rounds of plaque hybridization. 
By assaying the culture medium, we demonstrated recombinant virus infected Sl9 cells expressing hGM-CSF. Recombinant hGM-CSFs with appar- 
ent molecular masses of 14.5, 15.5 and 16.5 kDa were detected by the Western blot method. All 3 forms have biological activity of hGM-CSF. 
Following N-glycanase treatment, a single band of 14.5-15.5 kDa appeared in SDS-PAGE. Western blot analysis of expression in Sfp cells treated 
with tunicamycin revealed only the presence of the 14.5 kDa species. Thus, the signal sequence of recombinant hGM-CSF could be recognized 
and cleaved by infected insect cell and the resultant molecule secreted into the media. 
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1. INTRODUCTION 
Colony-stimulating factors (CSFs) are a group of 
glycoproteins required for the survival, proliferation 
and differentiation of hematopoietic ells [1,2]. One of 
these factors, hGM-CSF, stimulates the growth of 
granulocytes and macrophages. hGM-CSF has been ex- 
pressed in transfected COS cells [3,4] yeast [5,6] and E. 
cofi [7] by recombinant DNA techniques. The E. coli, 
yeast, and COS cell systems have disadvantages. hGM- 
CSF is expressed only transiently and at a relatively low 
level in transfected COS cells. Yeast-derived hGM-CSF 
is produced at somewhat higher levels, but can be 
derivatized with yeast-specific carbohydrate moieties. 
Expression in E. coli has other drawbacks, since E. coli 
neither synthesizes glycoproteins nor secretes proteins 
into the medium. The expression of hGM-CSF in the 
baculovirus-Spodoptera frugiperda (WI) cell system 
provides an alternative which can overcome these prob- 
lems. 
‘Coomassie stainable’ protein of the cell detected on 
SDS-polyacrylamide gels during a lytic infection. 
Because this gene is nonessential for replication or pro- 
duction of extracellular viruses in cultured cells, expres- 
sion vectors that use the strong AcNPV polyhedrin pro- 
moter to drive foreign genes have been developed [9]. 
By using this approach, large amounts of eucaryotic 
proteins have been successfully produced, including 
human fibroblast interferon [9], human c-myc protein 
[lo] and human interleukin-2 [ 111. In addition, insect 
cells can perform many of the higher eucaryotic post- 
translational modifications, including glycosylation [9], 
extracellular secretion [9,11], accurate peptide cleavage 
[9,11], and phosphorylation [lo]. These features of the 
baculovirus system make it attractive for the large-scale 
production of recombinant hGM-CSF. In this article, 
we describe the expression of hGM-CSF in Sf9 cells us- 
ing the Baculovirus Expression Vector System. 
The baculovirus Autographa californica nuclear 
polyhedrosis virus (AcNPV) is a very useful help- 
independent eucaryotic expression vector for the ex- 
pression of a wide variety of heterologous genes in large 
amounts [8]. A late gene product of AcNPV (poly- 
hedrin [9]) can account for up to 50% of the total 
2. MATERIALS AND METHODS 
2.1. Ceils and viruses 
Sf9 cells (ATCC, CRLl711) were grown at 27°C in TNM-FH (Gib- 
co, Grand Island, NY) containing 10% fetal bovine serum (Difco, 
Detroit, MI). The E2 strain of wild-type AcNPV and pAc373 were 
kindly provided by Dr Max Summers (Texas A&M University). Pro- 
cedures for the use of AcNPV as an expression vector have been 
described in detail [12]. 
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Abbreviations: hGM-CSF, human granulocyte-macrophage colony- 
stimulating factor; Sf9, Spodoptera frugiperda; AcNPV, Autographa 
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sulfate-polyacrylamide gel; hpi, hour postinfection 
The hGM-CSF sequence in the plasmid p91023(B) (ATCC, 39754) 
was transferred into the wild-type AcNPV genome by the following 
procedure. The segment of hGM-CSF cDNA was removed from 
p91023(B) by first digesting with EcoRI, filling in with Klenow frag- 
ment, ligating with BamHI linker, and then digesting with BamHI. 
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This segment was transferred into the bacntovirus ~~yh~~n plasmid 
pAc373 [I l] which had been digested with B~amHf and treated with 
bacterial alkaline phosphatase. A new construct (pAc373GM-CSF) is 
obtained, containing the intact coding sequence for GM-CSF in the 
proper orientation downstream of the strong polyhedrin promoter. 
pAc373GM-&SF DNA (2 fig) was subsequently co-transfected with 
wild-type AcNPV total viral DNA (1 agj into SF9 ceEs using calcium 
phosphate [13]. After 5 days ~stjnf~t~on at 27-C, a recomb~n~t 
bacJovirus was identified and purified by plaque hyb~di~atio~ [f2]. 
2.3. Pociuction of hGM-CSF in Sj9 cells 
The time course of hGM-CSF production in vAc373GMCSF- 
infected ceils was examined in order to detect the optimum time for 
hGM-CSF expression in the medmm. For this, ce& (2 x @) were 
seeded in 100 mm culture flasks and infected with wild-type or recom= 
binant viruses for I h at 27°C. The infected celfs were washed twice 
with TNM-FH medium and then incubated at 27’C in 10 ml of TNM- 
FH medium. The media were assayed for biological activity at 24,48, 
and 12 h postinfection (hpi), The presence of hGM-CSF-specific po]~ 
peptides was atso verified by Western blot analysis. 
hGM-CSF activity assay was performed with either human cord 
blood cdls [14, IS] or human bone marrow cdls 1161. Approximately 
2 X 10’ nonadherent manonuclear cells from cord blood or bone mwu”- 
row WM dispensed into each 35 mm Petri dishes containing the test 
sample+ Cdonies were cormted after lo-12 days. Aggregates of SO or 
more Cefls were scOr& as a colony using a dissectinf: microscope. 
After vAc373GM-CSF infection, conditioned media were prepared 
and hGM-CSF was analyzed by SDS-PAGE with the discontinuous 
system of Laemmli [17] Bnd then electrophoretically transferred to 
nitrocellulose for immunablat analysis 1181. The nitroceihdose fiber 
was probed with ~l~~o~ai rabbit anti-hGMKSF @enzyme, Boston, 
MA) and then developed with goat ~~-rab&it ~t~~y-h~ad~~ 
peroxidase conjugate, For analysis of hGM-CSF activity, the medimn 
at 72 hpi was electrophoresed on a 12% SDSPAGE gel. The gel W&S 
cut into 10 slices over the range from law molecular mass SpedcS 
(< 14 kDa) to 27 kDa, resulting in gel slices 0.25 cm in length and 
0.8 cm in width. Each slice was then extracted and assayed for bGM- 
C§F activity. 
SF9 cells infected with vAc373GM-CSF at 14 hpi were treated with 
5 fig tunicamycin/ml. After 3 days infection, the conditioned medium 
was collected and analyzed by Western blot. Further, to determine 
directly if hGM-CSF undergoes N-glycosylation in insect cells, pro- 
tein samples from media of infected Sf9 cells were adjusted to &.5% 
SDS and 0.1 M ~-rn~~ptoe~~ and boiled for 2 min. The 
disrupted sample was dihned 3-fold with 28@ mM sododium phosphate 
fpH 8.5). N-Glycanase @enzyme, Boston, MA) was added to a find 
concentration of 10 U/ml, After incubation for 16 h at 37’C, the 
sampXe was analyzed by Western blot. 
3. I * ~U~~f~~~~~~ and ~~~~~~~~~ ~~~~~~~~~~~# ~~~~~~ 
As shown in fig. is a segment of hGM-CSF DNA was 
inserted into the pAc373 transfer vector. A plasmid 
pAc373GMCSF was co-transfected into Sf9 cells with 
wild-type viral DNA. The isolation of she recombinant 
viruses was further demonstrate by their ability to pro- 
duce and secrete hGM-CSF into the medium. 
3.2. Production of )1GM-CSF activity in Sf9 cells 
Conditioned medium from insect cells infected with 
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Fig. I. Co~s~~~o~ of r~ornb~~a~t transfer vector ~A~373G~~~S~. 
The EcoRl fragment of hGM-CSFwas filled in with Menow frag- 
ment. BarnHI linkers were added with T4 DNA ligase. The fragment 
was treated with BumHI and inserted into the unique BarnHI site of 
the transfer vector. The resuhant plasmid, pAc37SGMCSF, contain- 
ed the hGM-CSF sequence placed downstream of the strong poly- 
he&in promoter. 
recombinsrnt viruses was assayed for hGM-CSF activity 
and analyzed for the presence of hGM-CSF protein by 
Western blot analysis. As shown in fig+2A, hGM-CSF 
activity in the medium was low, but detectable at 
24 hp& and steady a~~~rnu~a~on of hGM-CSF is 
observed up to 72 hpi. Assuming a hGM-CSF-specific 
activity of l-4 x 10’ U/mg [3], the highest accumula- 
tion of hGM-CSF in the medium (72 hpi) corresponds 
to an expression of 1 l-45 pglml (lo6 c&l/ml). Media 
from cells infected tith AcNPV had no detectable 
hGM-CSF activity. 
3.3. Idenfification of ht3WCSF from infected cells 
Conditioned medium of infected cells at 24, 48 and 
72 hpi was concentrated and run on SDS-PAGE, and 
proteins detected by Coomassie b&e staining and 
Western biot analysis using ~tj-hG~-CSF antibody 
(fig.28). Three proteins reacting with hGM-CSF anti- 
body were detected to have accumulated in the medium 
by 48 hpi, of molecular masses 14.5, 15.5 and 
16.5 kDa. This appears to suggest he expression of 3 
different forms of hGM-CSF in the infe-cted cells. The 
SDS-PAGE gel was cut and the get slices assayed for 
hGM-CSF activity (fig.3). Biological activity was found 
to be associated with gel slices over the range from 14 to 
17 kDa,, suggesting that 3 species of hGM-CSF are 
biofogically active. 
3.4. ~~Cos~Iafi~n ~~a~~~~ ~~$e~orn~~~~~~ &GM-CSF 
Tunicamycin, an inhibitor of all IV-glycosylation in 
glycoprotein biosynthesis [19], was used to determine 
the nature of glycosylation and its effect an the size of 
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Fig.2 Expression of hGM-CSF in Ac373 GM-CSF-infected Sf9 cells. 
Cells were infected with vAc373GM-CSF at a cell density of 106 
cells/ml. At 24, 48 and 72 h postinfection, samples were taken and 
(A) assayed for hGM-CSF activity as described In section 2. The 
hGM-CSF activity vA~373GM-CSF-(0) and AcNPV-(+) infected (B) 
dectrophoresed on a 12% SDS-PAGE get and stained with 
Coomassie blue or transferred to nitrocellulose for immunoblot 
analysis. Lane 1, lane 2 and lane 3 represent 24, 48 and 72 hpi in (a) 
Coomassie blue stain and (b) Western blot. Lane N is a set of protein 
standards. 
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Fig.3. hGM-CSF activity profile on SDS-PAGE. Conditioned 
medium from vAc373GM-CSF-infected cells was analyzed on a 12% 
SDS-PAGE 8el. The gel was sliced and assayed for hGM-CSF activity 
as described in section 2. 
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Fig.4. Effect of tu~~y~in (TM) on hGM-CSF secretion from Sf9 
cells. vAc373GM-CSF-infected Sf!? cells were treated with 5 pglmi 
tunicamycin at 14 hpi. At 72 hpi, samples were electrophoresed on a 
12% SDS-PAGE get and e~ectrophoreti~y transferred to nitro- 
cellulose for immunoblot analysis. (Lanes 1 and 2) Western blot 
analysis prepared from proteins with and without TM treatment, 
respectively. (Lane M) Molecular weight markers. 
the hGM-CSF in Sf9 cells. In the presence of tunica- 
mycin, the 15.5 and 16.5 kDa hGM-CSF glyc~proteins 
were missing and o&y the 14.5 kDa hGM-CSF aglyco- 
protein was shown by Western analysis. However, 
tuni~~yci~ had little effect on the production of the 
14.5 kDa hGM-CSF protein in vAc373GM-CSF- 
infected cells (fig.4). Furthermore, when the hGM-CSF 
from conditioned medium was treated with N- 
66.0 KDa 
45.0 KDa 
21.0 KDa 
44.4 kDa 
Fig.5 N-Glycanase analysis of insect cellderived hGM-CSF. The 
protein samples were treated with Ar-glycanase as described in section 
2. The reaction products were analyzed by Western blot, (Lanes 1 and 
2) Western blot analysis prepared from proteins with and without N- 
glycanase treatment, respectively. (Lane M) Mol~ular weight 
markers. 
251 
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glycanase, the 15.5 and 16.5 kDa of hGM-CSF was 
converted to a single species with a molecular mass of 
14.5-15.5 kDa (fig.5). The reduction of molecular 
weight of both bands by ~-glycanase treatment in- 
dicated that both bands are N-glycosylated protein. 
However, the microheterogeneity of these two proteins 
remain to be further characterized. 
4. DISCUSSION 
In this study, we used the Baculovirus Expression 
Vector System (BEVS) for the production of hGM-CSF 
in insect cells. The hGM-CSF produced in Sf9 cells is 
capable of stimulating colony formation in the cord 
blood cell assay. This suggests that the pre-hGM-CSF 
signal peptide was recognized and cleaved within Sf9 
cells and that the hGM-CSF is secreted into the medium 
during infection. 
Western blot analysis revealed the hGM-CSF produc- 
ed in the culture medium to have apparent molecular 
masses of 14.5, 15.5 and 16.5 kDa. The two larger 
bands result from glycosylation heterogeneity and the 
small one is an unglycosylated form as evidenced by the 
fact that a single band appears when these glycosylated 
proteins were treated with N-glycanase, or when in- 
fected Sf9 cells were treated with tu~~ycin. All 3 dif- 
ferent hGM-CSF forms secreted by insect cells show 
hGM-CSF activity, suggesting that differences exist in 
the posttranslational processing of the gene product re- 
sulting in 3 distinct but biologically active forms of the 
hGM-CSE. Multiple glycosylation products of express- 
ed hGM-CSF [ZO], haemagglutinin 1211 and mouse IL-3 
1221 have also been observed in this system. 
Many other mammalian glycoproteins expressed in 
insect cells, for example the human p-interferon [9], 
human epidermal growth factor receptor [23] and 
haemagglutinin or influenza virus 121.1, are synthesized 
as smaller glycoproteins than their naturally occu~ing 
counterparts. The complex type oligosaccharides com- 
monly occurring in glycoproteins of vertebrate cells 
have not been found in insect cell [24]. Instead, a much 
shorter and simpler oligosaccharide consisting of (Asn)- 
GlcNAcz-Man3 was commonly present in insect ceil 
glycoprotein. In characterizing the oligosaccharide 
nature of the product expressed in infected Sf9 cells, we 
observed that N-glycanase treatment of the hGM-CSF 
hydrolyzed the oligosaccharides from the hGM-CSF, 
reducing the 15.5 and 16.5 kDa forms to the size of 
14.5-15.5 kDa, presumably the core protein. The small 
change of molecular weight suggests that the hGM-CSF 
expressed lacks complex type oligosaccharide modifica- 
tions. The molecular mass of hGM-CSF expressed in 
this system of 14-17 kDa is comparable to that of 
22 kDa for hGM-CSF produced by MO cells [3] which 
would be expected to cont~n complex type oligosac- 
charide modifications. Additional work will be required 
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to further characterize the hGM-CSF oligosaccharide 
modifications observed in this study. 
Our results demonstrate that hGM-CSF protein is ex- 
pressed at a level of 11-45 mg/l by infected Sf9 cells. 
Although such expression is lower than that of the viral 
protein of polyhedrin (1200 mg/l), it is comparable to 
the expression of other recombinant proteins in this 
system such as c-myc [IO], EGF receptor [23] and inter- 
leukin-2 ill]. At this level of expression an adequate 
quantity of functional hGM-CSF protein can be obtain- 
ed for further physical-chemical analysis. 
Acknowledgements: This work was supported by USPHS Grants 
AM 21624, BRSG RR-05879 and a grant from The Robert A. Welch 
Foundation B-1058. The authors wish to thank Drs Robert Benj~in, 
Irma Pirtle and John Knesek for advice and technical assistance and 
Mrs Margie Schluter for preparation of manuscript. 
REFERENCES 
[l] Yunis, A.A., Wu, M.-C. and Miller, A.M. (1983) in: Colony- 
Stimulating Factor in Growth and Maturation Factors (Guroff, 
G. ed.) pp. 209-247, Wiley, New York. 
[Z] Metcalf, D. (1988) in: The Molecular Control of Blood Cells, pp. 
l-18, Harvard University Press, Cambridge. 
[3] Wong, G.G., Witek, J.S., Temple, P.A., Wilkens, K.M., Leary, 
AC., Luxenberg, D.P., Jones, S.S., Brown, E.L., Kay, R.M., 
Orr, EC., Shoemaker, C., Golde, D.W., Kaufman, R.J., 
Hewick, R.M., Wang, E.A. and Clark, S.C. (1985) Science 228, 
810-815. 
[4] Lee, F., Yokota, T., Otsuka, Y., Gemmell, L., Larson, N., Luh, 
J., Arai, K.-I. and Rennick, D. (1985) Proc. Natl. Acad. Sci. 
USA 82,4360-4364. 
[5] Cantreil, M.A., Anderson, D., Cerretti, D.P., Price, V., 
McKereghan, K., Tushinski, R.J., M~~zuki, D.Y., Larsen, 
A., Grabstein, K., Gillis, S. and Cosman, D. (198.5) Proc. Natl. 
Acad. Sci. USA 82,6250-6254. 
[6] Miyajima, A., Otsu, K., Schreurs, J., Bond, M.W., Abrams, 
J.S. and Arai, K. (1986) EMBO J. 5, 1193-1197. 
[7] Libby, R.T., Braedt, G., Kronheim, S.R., March, C.J., Urdal, 
D.L., Chiaverotti, T.A., Tushinski, R.J., Mochizuki, D.Y., 
Hopp, T-P. and Cosman, D. (1987) DNA 6, 221-229. 
[S] Luckow, V.A. and Summers, M.D. (1988) BioTechnoiogy 6, 
47-55. 
Vohne 259, number 2 FEBS LETTERS .hluary 1990 
[19] Takatsuki, A., Kohno, K. and Tamura, G. (1975) Agric. Biol. 
Chem. 39, 2089-2901. 
[Ztt] Maiorella, B., Inlow, D., Shauger, A. and Warano, D. (1988) 
BioT~hno~o~ 6, f406-1410. 
f2li Kuroda, K., Hauser, C., R&t, R., Klenk, N.-D. and Doefler, 
W. (1986) EMBO J. 5, 1359-1365. 
[22] Miyajima, A., Schreurs, J., Otsu, K., Kondo, A., Arai, K. and 
Maeda, S. (1987) Gene 58, 273-281. 
1231 Greenfield, C., Patd, G., Clark, S., Jones, N. and Waterfield, 
M.D. (1988) BMBG J. 7, 139-146. 
[24] II&h, P. and Robbins, P.W. (1984) J. Bioi. Chem. 259, 
2375-2382. 
253 
